1. Theodorides VJ, Gyurik RJ, Kingsbury WD, Parish RC. Anthelmintic activity of albendazole against liver flukes, tapeworms, lung and intestinal roundworms. Experientia 1976;32: 702-703
https://doi.org/10.1007/BF01919842.
2. Pene P, Mojon M, Garin JP, Coulaud JP, Rossignol JF. Albendazole: a new broad spectrum anthelmintic. Double-blind multicenter clinical trial. Am J Trop Med Hyg 1982;31: 263-266
https://doi.org/10.4269/ajtmh.1982.31.263.
4. Brugmans JP, Theinpont DC, Wijngaarden IV, Vanparijs OF, Schuermans VL, Lauwers HL. Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1,278 subjects. JAMA 1971;217: 313-316
https://doi.org/10.1001/jama.1971.03190030039008.
5. Pawluk SA, Roels CA, Wilby KJ, Ensom MHH. A review of pharmacokinetic drug-drug interactions with the anthelmintic medications albendazole and mebendazole. Clin Pharmacokinet 2015;54: 371-383
https://doi.org/10.1007/s40262-015-0243-9.
8. Chai JY, Hong ST. Chemotherapy of intestinal nematode infections. J Korean Soc Chemother 1985;3: 119-129.
12. Jamet D, Quinio D, Moalic E, Ianotto JC, Dalbies F, Guillerm G, Marion V, Berthou C, Nevez G. Systemic microsporidiosis and toxoplasmosis in a patient with T lymphocytic leukemia. Med Mal Infect 2009;39: 406-408 (in French).
https://doi.org/10.1016/j.medmal.2008.10.018.
14. Pungpark S, Bunnag D, Harinasuta T. Albendazole in the treatment of opisthorchiasis and concomitant intestinal helminthic infections. Southeast Asian J Trop Med Public Health 1984;15: 44-50.
16. Fan PC, Wu CC, Huang P, Yen CW. Determination of the minimum effective dosages of praziquantel, albendazole, and mebendazole against
Clonorchis sinensis infection in rats. Kaohsiung J Med Sci 2005;21: 448-451
https://doi.org/10.1016/S1607-551X(09)70149-4.
18. Xu LL, Jiang B, Duan JH, Zhuang SF, Liu YC, Zhu SQ, Zhang LP, Zhang HB, Xiao SH, Zhou XN. Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of
Clonorchis sinensis and other helminths. PLoS Negl Trop Dis 2014;8: e3046
https://doi.org/10.1371/journal.pntd.0003046.
19. Jaroonvesama N, Charoenlarp K, Cross JH. Treatment of Opisthorchis viverrini with mebendazole. Southeast Asian J Trop Med Public Health 1981;12: 595-597.
20. Dugernier T, Geubel A, Bigaignon G, Cesbron JY, Coche E. Human fascioliasis: cure by mebendazole? A case report. Gastroenterol Clin Biol 1986;10: 513-516.
21. Rim HJ, Joo KH, Park HS. Anthelmintic effects of albendazole against Taenia saginata and Taenia solium infections. J Korean Soc Chemother 1989;7: 29-39.
23. Steinmann P, Utzinger J, Du ZW, Jiang JY, Chen JX, Hattendorf J, Zhou H, Zhou XN. Efficacy of single-dose and triple-dose albendazole and mebendazole against soil-transmitted helminths and
Taenia spp.: a randomized controlled trial. PLoS One 2011;6: e25003
https://doi.org/10.1371/journal.pone.0025003.
24. Tamarozzi F, Nicoletti GJ, Neumayr A, Brunetti E. Acceptance of standardized ultrasound classification, use of albendazole, and long-term follow-up in clinical management of cystic echinococcosis: a systematic review. Curr Opin Infect Dis 2014;27: 425-431
https://doi.org/10.1097/QCO.0000000000000093.
25. Qavi A, Garg RK, Malhotra HS, Jain A, Kumar N, Malhotra KP, Srivastava PK, Verma R, Sharma PK. Disseminated cysticercosis: clinical spectrum, Toll-like receptor-4 gene polymorphisms and role of albendazole. Medicine 2016;95: e4882
https://doi.org/10.1097/MD.0000000000004882.
26. Molina JM, Oksenhendler E, Beauvais B, Sarfati C, Jaccard A, Derouin F, Modaï J. Disseminated microsporidiosis due to
Septata intestinalis in patients with AIDS: clinical features and response to albendazole therapy. J Infect Dis 1995;171: 245-249
https://doi.org/10.1093/infdis/171.1.245.
27. Sak B, Brdíčková K, Holubová N, Květoňová D, Hlásková L, Kváč M.
Encephalitozoon cuniculi genotype III evinces a resistance to albendazole treatment in both immunodeficient and immunocompetent mice. Antimicrob Agents Chemother 2020;64: e00058-20
https://doi.org/10.1128/AAC.00058-20.
28. Darlan DM, Hartanto SJ, Rozi MF. The comparison of efficacy and side effect between albendazole and metronidazole in the management of giardiasis: a systematic review and meta-analysis. EuroMeditter Biomed J 2020;15: 191-196
https://doi.org/10.3269/1970-5492.2020.15.45.
29. Palos I, Moo-Puc R, Vique-Sánchez JL, Benítez-Cardoza CG, Monge A, Villalobos-Rocha JC, Paz-Gonzalez AD, Rivera G. Esters of quinolone-7-carboxylate-1,4-di-
N-oxide as
Trichomonas vaginalis triosephosphate isomerase inhibitors. Acta Pharm 2021;71: 485-495
https://doi.org/10.2478/acph.2021-0032.
30. Sears SD, O’hare J. In vitro susceptibility of
Trichomonas vaginalis to 50 antimicrobial agents. Antimicrobial Agents Chemother 1988;32: 144-146
https://doi.org/10.1128/AAC.32.1.144.
31. Cedillo-Rivera R, Muñoz O. In-vitro susceptibility of
Giardia lamblia to albendazole, mebendazole and other chemotherapeutic agents. J Med Microbiol 1992;37: 221-224
https://doi.org/10.1099/00222615-37-3-221.
32. Patziarka P, Bouche G, Meheus L, Sukhatme V, Sukhatme VP. Repurposing drugs in oncology (ReDO)-mebendazole as an anti-cancer agent. Ecancermedicalscience 2014;8: 443
https://doi.org/10.3332/ecancer.2014.44332..
33. Castro LSEPW, Kviecinski MR, Ourique F, Parisotto EB, Grinevicius VMAS, Correia JFG, Filho DW, Pedrosa RC. Albendazole as a promising molecule for tumor control. Radix Biol 2016;10: 90-99
https://doi.org/10.1016/j.redox.2016.09.013.
34. Guerini AE, Triggiani L, Maddalo M, Bonù ML, Frassine F, Baiguini A, Alghisi A, Tomasini D, Borghetti P, Pasinetti N, Bresciani R, Magrini SM, Buglione M. Mebendazole as a candidate for drug repurposing in oncology: an extensive review of current literature. Cancers 2019;11: 1284
https://doi.org/10.3390/cancers11091284.
37. Morris DL, Jourdan JL, Pougholami MH. Pilot study of albendazole in patients with advanced malignancy. Oncology 2001;61: 42-46
https://doi.org/10.1159/000055351.
38. Pourgholami MH, Woon L, Almajd R, Akhter J, Bowery P, Morris DL. In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole. Cancer Lett 2001;165: 43-49
https://doi.org/10.1016/S0304-3835(01)00382-2.
40. Krücken J, Fraundorfer K, Mugisha JC, Ramünke S, Sifft KC, Geus D, Habarugira F, Ndoli J, Sendegeya A, Mukampunga C, Bayingana C, Aebischer T, Demeler J, Gahutu JB, Mockenhaupt FP, von Samson-Himmelstjerna G. Reduced efficacy of albendazole against
Ascaris lumbricoides in Rwandan schoolchildren. Int J Parasitol Drugs Drug Resist 2017;7: 262-271
https://doi.org/10.1016/j.ijpddr.2017.06.001.
41. Rashwan N, Bourguinat C, Keller K, Gunawardena NK, de Silva N, Prichard R. Isothermal diagnostic assays for monitoring single nucleotide polymorphisms in
Necator americanus associated with benzimidazole drug resistance. PLoS Negl Trop Dis 2016;10: e0005113
https://doi.org/10.1371/journal.pntd.0005113.
43. Moser W, Schindler C, Keiser J. Efficacy of recommended drugs against soil transmitted helminths: systematic review and network meta-analysis. BMJ 2017;358: j4307
https://doi.org/10.1136/bmj.j4307.
44. Soukhathammavong PA, Sayasone S, Phongluxa K, Xayaseng V, Utzinger J, Vounatsou P, Hatz C, Akkhavong K, Keiser J, Odermatt P. Low efficacy of single-dose albendazole and mebendazole against hookworm and effect on concomitant helminth infection in Lao PDR. PLoS Negl Trop Dis 2012;6: e1417
https://doi.org/10.1371/journal.pntd.0001417.
45. World Health Organization. WHO Model Prescribing Information: Drugs Used in Parasitic Diseases. 2nd ed. World Health Organization. Geneva, Switzerland. 1995, pp 1-146.
46. Chai JY, Sohn WM, Hong SJ, Jung BK, Hong S, Cho S, Park JB, Kim IS, Kim S, Lee KH, Jeoung HG, Htoon TT, Tin HH. Effect of mass drug administration with a single dose of albendazole on
Ascaris lumbricoides and
Trichuris trichiura infection among schoolchildren in Yangon Region, Myanmar. Korean J Parasitol 2020;58: 195-200
https://doi.org/10.3347/kjp.2020.58.2.195.
47. Chaia G, Sales da Cunha A. Therapeutic action of mebendazole (R 17,635) against human helminthiasis. Fôlha Med 1971;63: 843-852.
51. Pene P, Coulaud JP, Soula G, Rossignol JF, Monges P, Chaudet H. Le Zentel® dans traitement des helminthiases intestinales en Afrique de l’Ouest. Méd Afr Noire 1982;29: 43-48 (in French).
52. Soula G, Stopathis RM. Le Zentel® dans le traitement des nématodoses intestinales en République Centrafricaine. Méd Afr Noire 1982;29: 29-32 (in French).
54. Seo BS, Cho SY, Kang SY, Chai JY. Anthelmintic efficacy of methyl-5-benzoylbenzimidazle-2-carbamate (mebendazole) against multiple helminthic infections. Korean J Parasitol 1977;15: 11-16
http://dx.doi.org/10.3347/kjp.1977.15.1.11.
55. Sinniah B, Sinniah D, Dissanaike AS. Treatment of intestinal nematodes with single dose treatment of oxantel-pyrantel pamoate plus mebendazole. Asian Parasite Control Organization Research Group. Collected Papers on the Control of Soil-Transmitted Helminthiases by Asian Parasite Control Organization (APCO). Tokyo, Japan. The Asian Parasite Control Organization. 1980, pp 321-325.
56. Coulaud JP, Duchatelle C, Rouvillois A, Deluol AM. Le Zentel® dans le traitement des helminthiases intestinales, au Niger, en Guinée et à Paris. Méd Afr Noire 1982;29: 41-42 (in French).
57. Kim CH. Clinical trials of mebendazole (Vermox) on Ascaris and Trichuris infection. Chungnam Med J 1975;2: 207-211 (in Korean).
59. Henriquez-Camacho C, Gottuzzo E, Echevarria J, White AC Jr, Terashima A, Samalvides F, Pérez-Molina JA, Plana MN. Ivermectin versus albendazole or thiabendazole for
Strongyloides stercoralis infection. Cochrane Datab Syst Rev; 2016. 2016: CD007745
http://doi.org/10.1002/14651858.CD007745.pub3.
61. Echazú A, Juarez M, Vargas PA, Cajal SP, Cimino RO, Heredia V, Caropresi S, Paredes G, Arias LM, Abril M, Gold S, Lammie P, Krolewiecki AJ. Albendazole and ivermectin for control of soil-transmitted helminths in an area with high prevalence of
Strongyloides stercoralis and hookworm in northwestern Argentina: a community-based pragmatic study. PLoS Negl Trop Dis 2017;11: e0006003
http://doi.org/10.1371/journal.pntd.0006003.
62. Chai JY, Hong ST, Sohn WM, Lee SH. Anthelmintic effect of albendazole (Alzental@) on human intestinal nematodes. J Korean Soc Chemother 1986;4: 86-88 (in Korean).
64. Cho SY, Ahn YR, Ryang YS, Seo BS. Evaluation of anthelmintic treatment on
Enterobius vermicularis infection in highly endemic population by prolonged observation. Korean J Parasitol 1977;15: 100-108
http://dx.doi.org/10.3347/kjp.1977.15.2.100.
66. Steinmann P, Zhou XN, Du ZW, Jiang JY, Xiao SH, Wu ZX, Zhou H, Utzinger J. Tribendimidine and albendazole for treating soil-transmitted helminths,
Strongyloides stercoralis and
Taenia spp.: open-label randomized trial. PLoS Negl Trop Dis 2008;2: e322
https://doi.org/10.1371/journal.pntd.0000322.
67. Soh CT, Lee BH, Min DY, Chang SJ, Lee JH. Clinical trial of Vermox (mebendazole), a new broadspectrum anthelmintic. Yonsei Rep Trop Med 1974;5: 148-152.
74. Stürchler D, Schubarth P, Gualzata M, Gottstein B, Oettli A. Thiabendazole vs. albendazole in treatment of toxocariasis: a clinical trial. Ann Trop Med Parasitol 1989;83: 473-478
https://doi.org/10.1080/00034983.1989.11812374.
75. Barisani-Asenbauer T, Maca SM, Hauff W, Kaminski SL, Domanovits H, Theyer I, Auer H. Treatment of ocular toxocariasis with albendazole. J Ocul Pharmacol Therapeut 2001;17: 287-294
https://doi.org/10.1089/108076801750295317.
76. . Drugs for parasitic infections. Med Lett Drugs Ther 2004;1189: 1-12.
78. Feske SK, Goldberg M, Dudzinski DM, Gonzalez RG, Kovach AE. Case 29-2015: a 38-year-old pregnant woman with headache and visual symptoms. N Engl J Med 2015;373: 1154-1164
https://doi.org/10.1056/NEJMcpc1404335.
80. Hombu A, Yoshida A, Kikuchi T, Nagayasu E, Kuroki M, Maruyama H. Treatment of larva migrans syndrome with long-term administration of albendazole. J Microbiol Immunol Infect 2019;52: 100-105
https://doi.org/10.1016/j.jmii.2017.07.002.
82. Coulaud JP, Binet D, Voyer C, Samson C, Moreau G, Rossignol JF. Treatment of cutaneous larva migrans “Larbish’ with albendazole: report of 18 cases. Bull Soc Pathol Exot Filiales 1982;75: 534-537 (in French).
83. Thadchanamoorthy V, Dayasiri K. Cutaneous larvae migrans infestation over buttocks and perianal region: a case series of five toddlers from Sri Lanka and literature review. Cureus 2020;12: e11335
https://doi.org/10.7759/cureus.11335.
84. Mulia RC, Djawad K, Adriani A, Idrus I. Office-made 4% albendazole cream is an effective alternative therapy for cutaneous larva migrans: a report of three cases. Serbian J Dermatol Venerol 2020;12: 9-13
https://doi.org/10.2478/sjdv-2020-0002.
86. Sohn WM, Chai JY. Chapter 63. Anisakiosis (Anisakidosis). Part 4. Parasitic zoonoses. In Palmer SR, Soulsby L, Torgerson P, Brown DWG eds, Oxford Textbook of Zoonoses: Biology, Clinical Practice, and Public Health Control. 2nd ed. Oxford Univ Press. London, UK. 2011, pp 776-788.
87. Lim H, Jung BK, Cho J, Yooyen T, Shin EH, Chai JY. Molecular diagnosis of cause of anisakiasis in humans, South Korea. Emerg Infect Dis 2015;21: 342-344
https://doi.org/10.3201/eid2102.140798.
89. Pacios E, Arias-Diaz J, Zuloaga J, Gonzalez-Armengol J, Villarroel P, Balibrea JL. Albendazole for the treatment of anisakiasis ileus. Clin Infect Dis 2005;41: 1825-1826
https://doi.org/10.1086/498309.
90. Baptista-Fernandes T, Rodrigues M, Castro I, Paixão P, Pinto-Marques P, Roque L, Belo S, Ferreira PM, Mansinho K, Toscano C. Human gastric hyperinfection by
Anisakis simplex: a severe and unusual presentation and a brief review. Int J Infect Dis 2017;64: 38-41
https://doi.org/10.1016/j.ijid.2017.08.012.
91. Guardone L, Armani A, Nucera D, Costanzo F, Mattiucci S, Bruschi F. Human anisakiasis in Italy: a retrospective epidemiological study over two decades. Parasite 2018;25: 41
https://doi.org/10.1051/parasite/2018034.
92. Maggi P, Caputi-Lambrenghi O, Scardigno A, Scoppetta L, Saracino A, Valente M, Pastore G, Angarano G. Gastrointestinal infection due to
Anisakis simplex in southern Italy. Eur J Epidemiol 2000;16: 75-78
https://doi.org/10.1023/a:1007617002972.
93. Moschella CM, Mattiucci S, Mingazzini P, De Angelis G, Assenza M, Lombardo F, Monaco S, Paggi L, Modini C. Intestinal anisakiasis in Italy: case report. J Helminthol 2004;78: 271-273
https://doi.org/10.1079/JOH2004237.
94. Gómez-Mateos M, Arrebola F, Navarro MC, Romero MC, González JM, Valero A. Acute anisakiasis: pharmacological evaluation of various drugs. Dig Dis Sci 2021;66: 105-113
https://doi.org/10.1007/s10620-020-06144-2.
95. McCracken RO. Efficacy of mebendazole and albendazole against
Trichinella spiralis in mice. J Parasitol 1978;64: 214-219
https://doi.org/10.2307/3279659.
96. Fourestié V, Bougnoux ME, Ancelle T, Liance M, Roudot-Thoraval F, Naga H, Pairon-Pennachioni M, Rauss A, Lejonc JL. Randomized trial of albendazole versus tiabendazole plus flubendazole during an outbreak of human trichinellosis. Parasitol Res 1988;75: 36-41
https://doi.org/10.1007/BF00931188.
97. Cabié A, Bouchaud O, Houzé S, Khuong MA, Ruggeri C, Ancelle T, Matheron S, Coulaud JP. Albendazole versus thiabendazole as therapy for trichinosis: a retrospective study. Clin Infect Dis 1996;22: 1033-1035
https://doi.org/10.1093/clinids/22.6.1033.
99. Dupouy-Camet J, Kociecka W, Bruschi F, Bolas-Fernandez F, Pozio E. Opinion on the diagnosis and treatment of human trichinellosis. Expert Opin Pharmacother 2002;3: 1117-1130
https://doi.org/10.1517/14656566.3.8.1117.
100. Bruschi F, Murrell KD. Chapter 119. Trichinellosis. Part 6. Helminthic infections. In Strickland GT, Hunter GW eds, Hunter’s Tropical Medicine and Emerging Infectious Diseases. 8th ed. Philadelphia, USA. Saunders. 2000, pp 882-884.
101. López-García ML, Torrado S, Torrado S, Martínez AR, Bolás F. Methimazole-mediated enhancement of albendazole oral bioavailability and anthelmintic effects against parenteral stages of
Trichinella spiralis in mice: the influence of the dose-regime. Vet Parasitol 1998;75: 209-219
https://doi.org/10.1016/S0304-4017(97)00177-5.
102. Kalaiselvan R, Mohanta GP, Madhusudan S, Manna PK, Manavalan R. Enhancement of bioavailability and anthelmintic efficacy of albendazole by solid dispersion and cyclodextrin complexation techniques. Pharmazie 2007;62: 604-607
https://doi.org/10.1691/ph.2007.8.6274.
103. Eid RK, Ashour DS, Essa EA, El Maghraby GM, Arafa MF. Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against
Trichinella spiralis. Carbohyd Polym 2020;232: 115826
https://doi.org/10.1016/j.carbpol.2019.115826.
104. Fernando SSE, Denham DA. The effects of mebendazole and fenbendazole on
Trichinella spiralis in mice. J Parasitol 1976;62: 874-876
https://doi.org/10.2307/3279176.
107. Pozio E, Sacchini D, Sacchi L, Tamburrini A, Alberici F. Failure of mebendazole in the treatment of humans with
Trichinella spiralis infection at the stage of encapsulating larvae. Clin Infect Dis 2001;32: 638-642
https://doi.org/10.1086/318707.
110. Sawamura R, Fernandes MI, Peres LC, Galvão LC, Goldani HA, Jorge SM, de Melo Rocha G, de Souza NM. Hepatic capillariasis in children: report of 3 cases in Brazil. Am J Trop Med Hyg 1999;61: 642-647
https://doi.org/10.4269/ajtmh.1999.61.642.
112. Cross JH, Basaca-Sevilla V. Albendazole in the treatment of intestinal capillariasis. Southeast Asian J Trop Med Public Health 1987;18: 507-510.
113. Lee SH, Hong ST, Chai JY, Kim WH, Kim YT, Song IS, Kim SW, Choi BI, Cross JH. A case of intestinal capillariasis in the Republic of Korea. Am J Trop Med Hyg 1993;48: 542-546
https://doi.org/10.4269/ajtmh.1993.48.542.
115. Bair MJ, Hwang KP, Wang TE, Liou TC, Lin SC, Kao CR, Wang TY, Pang KK. Clinical features of human intestinal capillariasis in Taiwan. World J Gastroenterol 2004;10: 2391-2393
https://doi.org/10.3748/wjg.v10.i16.2391.
116. Soukhathammavong P, Sayasone S, Harimanana AN, Akkhavong A, Thammasack S, Phoumindr N, Choumlivong K, Choumlivong K, Keoluangkhot V, Phongmany S, Akkhavong K, Hatz C, Strobel M, Odermatt P. Three cases of intestinal capillariasis in Lao People’s Democratic Republic. Am J Trop Med Hyg 2008;79: 735-738
https://doi.org/10.4269/ajtmh.2008.79.735.
117. Rana SS, Bhasin DK, Bhatti HS, Gupta K, Gupta R, Nada R, Nagi B, Sinha SK, Singh K. Human intestinal capillariasis: diagnosis by jejunal fluid analysis obtained at enteroscopy and reversal of subtotal villous atrophy after treatment. Endoscopy 2009;41(suppl):102-103
https://doi.org/10.1055/s-0028-1119609.
118. Sadaow L, Sanpool O, Intapan PM, Sukeepaisarnjaroen W, Prasongdee TK, Maleewong W. A hospital-based study of intestinal capillariasis in Thailand: clinical features, potential clues for diagnosis, and epidemiological characteristics of 85 patients. Am J Trop Med Hyg 2018;98: 27-31
https://doi.org/10.4269/ajtmh.17-0465.
119. Alcantara AK, Uylangco CV, Cross JH. An obstinate case of intestinal capillariasis. Southeast Asian J Trop Med Public Health 1985;16: 410-413.
120. Hoghooghi-Rad N, Maraghi S, Narenj-Zadeh A.
Capillaria philippinensis infection in Khoozestan province, Iran: case report. Am J Trop Med Hyg 1987;37: 135-137
https://doi.org/10.4269/ajtmh.1987.37.135.
121. Dronda F, Chaves F, Sanz A, Lopez-Velez R. Human intestinal capillariasis in an area of nonendemicity: case report and review. Clin Infect Dis 1993;17: 909-912
https://doi.org/10.1093/clinids/17.5.909.
123. Hwang KP, Chen ER. Clinical studies on angiostrongyliasis cantonensis among children in Taiwan. Southeast Asian J Trop Med Public Health 1991;22(suppl):194-199.
124. Wang X, Huang H, Dong Q, Lin Y, Wang Z, Li F, Nawa Y, Yoshimura K. A clinical study of eosinophilic meningoencephalitis caused by angiostrongyliasis. Chin Med J 2002;115: 1312-1315.
125. Chotmongkol V, Wongjitrat C, Sawadpanit K, Sawanyawisuth K. Treatment of eosinophilic meningitis with a combination of albendazole and corticosteroid. Southeast Asian J Trop Med Public Health 2004;35: 172-174.
126. Wang J, Qi H, Diao Z, Zheng X, Li X, Ma S, Ji A, Yin C. An outbreak of angiostrongyliasis cantonensis in Beijing. J Parasitol 2010;96: 377-381
https://doi.org/10.1645/GE-2214-1.
128. Tsai HC, Liu YC, Kunin CM, Lee SS, Chen YS, Lin HH, Tsai TH, Lin WR, Huang CK, Yen MY, Yen CM. Eosinophilic meningitits caused by
Angiostrongylus cantonensis: report of 17 cases. Am J Med 2001;111: 109-114
https://doi.org/10.1097/MD.0000000000010975.
129. Chotmongkol V, Sawadpanitch K, Sawanyawisuth K, Louhawilai S, Limpawattana P. Treatment of eosinophilic meningitis with a combination of prednisolone and mebendazole. Am J Trop Med Hyg 2006;74: 1122-1124
https://doi.org/10.4269/ajtmh.2006.74.1122.
130. Leone S, De Marco M, Ghirga P, Nicastri E, Esposito M, Narciso P. Eosinophilic meningitis in a returned traveler from Santo Domingo: case report and review. J Travel Med 2007;14: 407-410
https://doi.org/10.1111/j.1708-8305.2007.00152.x.
131. Hermes CC, Benvegnú E, Costa MM, Rodriguez R, Vieira MIB. Abdominal angiostrongyliasis: pathologic findings in Swiss mice infected with different doses of
Angiostrongylus costaricensis. J Helminthol 2020;94: e169
https://doi.org/10.1017/S0022149X20000516.
132. Dekumyoy P, Watthanakulpanich D. Chapter 121. Gnathostomiasis. Part 6. Helminthic Infections. In Ryan ET, Hill DR, Solomon T, Aronson NE, Endy TP eds, Hunter’s Tropical Medicine and Emerging Infectious Diseases. 10th ed. Edinburgh, Scotland. Elsevier. 2020, pp 888-890.
133. Kraivichian K, Kulkumthorn M, Yingyourd P, Akarabovorn P, Paireepai CC. Albendazole for the treatment of human gnathostomiasis. Trans R Soc Trop Med Hyg 1992;86: 418-421
https://doi.org/10.1016/0035-9203(92)90248-B.
135. Nontasut P, Claesson BA, Dekumyoy P, Pakdee W, Chullawichit S. Double-dose ivermectin vs albendazole for the treatment of gnathostomiasis. Southeast Asian J Trop Med Public Health 2005;36: 650-652.
136. Kraivichian K, Nuchprayoon S, Sitichalernchai P, Chaicumpa W, Yentakam S. Treatment of cutaneous gnathostomiasis with ivermectin. Am J Trop Med Hyg 2004;71: 623-628
https://doi.org/10.4269/ajtmh.2004.71.623.
137. Haddad V Junior, Oliveira ÍF, Bicudo NP, Marques MEA. Gnathostomiasis acquired after consumption of raw freshwater fish in the Amazon region: a report of two cases in brazil. Rev Soc Bras Med Trop 2021;54: e20200127
https://doi.org/10.1590/0037-8682-0127-2020.
138. Chai JY, Han ET, Shin EH, Park JH, Chu JP, Hirota M, Nakamura-Uchiyama F, Nawa Y. An outbreak of gnathostomiasis among Korean emigrants in Myanmar. Am J Trop Med Hyg 2003;69: 67-73
https://doi.org/10.4269/ajtmh.2003.69.67.
140. Sharma C, Piyaphanee W, Watthanakulpanich D. Case report: clinical features of intermittent migratory swelling caused by gnathostomiasis with complete follow-up. Am J Trop Med Hyg 2017;97: 1611-1615
https://doi.org/10.4269/ajtmh.17-0239.
142. Raharisoa A, Izri A, Andrianjafy RL, Rajaona RA, Marteau A, Durand R, Akhoundi M. Autochthonous gnathostomiasis in Madagascar. Emerg Infect Dis 2020;26: 1875-1877
https://doi.org/10.3201/eid2608.200383.
144. Wilson ME, Lorente CA, Allen JE, Eberhard ML.
Gongylonema infection of the mouth in a resident of Cambridge, Massachusetts. Clin Infect Dis 2001;32: 1378-1380
https://doi.org/10.1086/319991.
147. Xiaodan L, Zhensheng W, Ying H, Hongwei L, Jiangqiu J, Peiru Z, Sha S, Zhimin Y.
Gongylonema pulchrum infection in the human oral cavity: a case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol 2018;125: e49-e53
https://doi.org/10.1016/j.oooo.2017.11.019.
148. Libertin CR, Reza M, Peterson JH, Lewis J, Hata DJ. Human
Gongylonema pulchrum infection: esophageal symptoms and need for prolonged albendazole therapy. Am J Trop Med Hyg 2017;96: 873-875
https://doi.org/10.4269/ajtmh.16-0852.
149. Kudo N, Kubota H, Gotoh H, Ishida H, Ikadai H, Oyamada T. Efficacy of thiabendazole, mebendazole, levamisole and ivermectin against gullet worm,
Gongylonema pulchrum: in vitro and in vivo studies. Vet Parasitol 2008;151: 46-52
https://doi.org/10.1016/j.vetpar.2007.10.005.
150. do Vale B, Lopes AP, Fontes MC, Silvestre M, Cardoso L, Coelho AC. Thelaziosis due to
Thelazia callipaeda in Europe in the 21st century-a review. Vet Parasitol 2019;275: 108957
https://doi.org/10.1016/j.vetpar.2019.108957.
151. Calero-Bernal R, Sánchez-Murillo JM, Alarcón-Elbal PM, Sánchez-Moro J, Latrofa MS, Dantas-Torres F, Otranto D. Resolution of canine ocular thelaziosis in avermectin-sensitive Border Collies from Spain. Vet Parasitol 2014;200: 203-206
https://doi.org/10.1016/j.vetpar.2013.12.014.
152. Sharma M, Das D, Bhattacharjee H, Islam S, Deori N, Bharali G, Tomar S, Bhola P, Deka A. Human ocular thelaziasis caused by gravid
Thelazia callipaeda-a unique and rare case report. Ind J Ophthalmol 2019;67: 282-285
https://doi.org/10.4103/ijo.IJO_1110_18.
154. Eberhard ML, Brandt FH, Ruiz-Tiben E, Hightower A. Chemoprophylactic drug trials for treatment of dracunculiasis using the
Dracunculus insignis-ferret model. J Helminthol 1990;64: 79-86
https://doi.org/10.1017/S0022149X00011962.
159. García HH, Evans CA, Nash TE, Takayanagui OM, White AC Jr, Botero D, Rajshekhar V, Tsang VC, Schantz PM, Allan JC, Flisser A, Correa D, Sarti E, Friedland JS, Martinez SM, Gonzalez AE, Gilman RH, Del Brutto OH. Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 2002;15: 747-756
https://doi.org/10.1128/CMR.15.4.747-756.2002.
161. Arroyo G, Bustos JA, Lescano AG, Gonzales I, Saavedra H, Rodriguez S, Pretell EJ, Bonato PS, Lanchote VL, Takayanagui OM, Horton J, Gonzalez AE, Gilman RH, Garcia HH. Cysticercosis Working Group in Peru . Albendazole sulfoxide plasma levels and efficacy of antiparasitic treatment in patients with parenchymal neurocysticercosis. Clin Infect Dis 2019;69: 1996-2002
https://doi.org/10.1093/cid/ciz085.
163. Surve A, Goel S, Bajaj MS, Pujari A. Extraocular muscle cysticercosis: never skip steroids. BMJ Case Rep 2018;2018: 1-2
https://10.1136/bcr-2017-223356.
164. Palomares-Alonso F, Toledo A, Palencia Hernández G, Jung-Cook H, Fleury A. Effect of dexamethasone on albendazole cysticidal activity in experimental cysticercosis by
Taenia crassiceps in BALB/c mice: in vivo and in vitro evaluation. Exp Parasitol 2020;208: 107801
https://doi.org/10.1016/j.exppara.2019.107801.
166. Heath DD, Christie MJ, Chevis RAF. The lethal effect of mebendazole on secondary
Echinococcus granulosus, cysticerci of
Taenia pisiformis and tetrathyridia of
Mesocestoides corti. Parasitology 1975;70: 273-285
https://doi.org/10.1017/S0031182000049738.
167. Francisca PA, Javier LF, Guadalupe PH, Fernanda GM, Nelly C, Helgi JC, Iliana GH, Susana RTI. Cysticidal activity of praziquantel-mebendazole combination: in vitro and in vivo studies. Acta Trop 2019;202: 105238
https://doi.org/10.1016/j.actatropica.2019.105238.
168. Hemphill A, Stadelmann B, Rufener R, Spiliotis M, Boubaker G, Müller J, Müller N, Gorgas D, Gottstein B. Treatment of echinococcosis: albendazole and mebendazole-what else? Parasite 2014;21: 70
https://doi.org/10.1051/parasite/2014073.
169. Velasco-Tirado V, Alonso-Sardón M, Lopez-Bernus A, Romero-Alegría Á, Burguillo FJ, Muro A, Carpio-Pérez A, Muñoz Bellido JL, Pardo-Lledias J, Cordero M, Belhassen-García M. Medical treatment of cystic echinococcosis: systematic review and meta-analysis. BMC Infect Dis 2018;18: 306
https://doi.org/10.1186/s12879-018-3201-y.
172. Todorov T, Vutova K, Mechkov G, Georgiev P, Petkov D, Tonchev Z, Nedelkov G. Chemotherapy of human cystic echinococcosis: comparative efficacy of mebendazole and albendazole. Ann Trop Med Parasitol 1992;86: 59-66
https://doi.org/10.1080/00034983.1992.11812631.
176. Mohamed AE, Yasawy MI, Karawi MAA. Combined albendazole and praziquantel versus albendazole alone in the treatment of hydatid disease. Hepatogastroenterology 1998;45: 1690-1694.
177. Cobo F, Yarnoz C, Sesma B, Fralle P, Aizcorbe M, Trujillo R, Diaz-de-Liaño A, Ciga MA. Albendazole plus praziquantel versus albendazole alone as a pre-operative treatment in intra-abdominal hydatidosis caused by
Echinococcus granulosus. Trop Med Int health 1998;3: 462-466
https://doi.org/10.1046/j.1365-3156.1998.00257.x.
179. Khuroo MS, Dar MY, Yattoo GN, Zargar SA, Javaid G, Khan BA, Boda MI. Percutaneous drainage versus albendazole therapy in hepatic hydatidosis: a prospective, randomized study. Gastroenterology 1993;104: 1452-1459
https://doi.org/10.1016/0016-5085(93)90355-G.
180. Khuroo MS, Wani NA, Javaid G, Khan BA, Yattoo GN, Shah AH, Jeelani SG. Percutaneous drainage compared with surgery for hepatic hydatid cysts. N Engl J Med 1997;337: 881-887
https://doi.org/10.1056/NEJM199709253371303.
181. Smego RA Jr, Bhatti S, Khaliq AA, Beg MA. Percutaneous aspiration-injection-reaspiration drainage plus albendazole or mebendazole for hepatic cystic echinococcosis: a meta-analysis. Clin Infect Dis 2003;37: 1073-1083
https://doi.org/10.1086/378275.
182. Örmeci N, Kalkan Ç, Karakaya F, Erden A, Köse KS, Tüzün AE, Deda X. Percutaneous treatment with the Örmeci technique of cystic echinococcosis: experience of single center. Gastroenterol Hepatol Open Access 2020;11: 223-230
https://doi.org/10.15406/ghoa.2020.11.00443.
184. Bekhti A, Schaaps JP, Capron M, Dessaint JP, Santoro F, Capron A. Treatment of hepatic hydatid disease with mebendazole: preliminary results in four cases. Br Med J 1977;2: 1047-1051
https://doi.org/10.1136/bmj.2.6094.1047.
185. Verheyen A.
Echinococcus granulosus: the influence of mebendazole therapy on the ultrastructural morphology of the germinal layer of hydatid cysts in humans and mice. Z Parazitenkd 1982;67: 55-65
https://doi.org/10.1007/BF00929514.
187. Salto E, Juárez E, Roiz MP, Abad J. Combined chemotherapy (mebendazole plus praziquantel) in patients with hydatidosis. Enferm Infecc Microbiol Clin 1991;9: 527-529 (in Spanish).
https://europepmc.org/article/med/1822703.
188. Vutova K, Mechkov G, Vachkov P, Petkov R, Georgiev P, Handjiev S, Ivanovh A, Todorov T. Effect of mebendazole on human cystic echinococcosis: the role of dosage and treatment duration. Ann Trop Med Parasitol 1999;93: 357-365
https://doi.org/10.1080/00034983.1999.11813432.
191. Kimura E, Penaia L, Spears GFS. The efficacy of annual single-dose treatment with diethylcarbamazine citrate against diurnally subperiodic bancroftian filariasis in Samoa. Bull World Health Organ 1985;63: 1097-1106.
193. Moulia-Pelat JP, Glaziou P, Weil GJ, Nguyen LN, Gaxotte P, Nicolas L. Combination ivermectin plus diethylcarbamazine, a new effective tool for control lymphatic filariasis. Trop Med Parasitol 1995;46: 9-12
https://europepmc.org/article/med/7631132.
194. Jayakody RL, De Silva CSS, Weerasinghe WMT. Treatment of bancroftian filariasis with albendazole: evaluation of efficacy and adverse reactions. Trop Biomed 1993;10: 19-24.
195. Addiss DA, Beach MJ, Streit TG, Lutwick S, LeConte FH, Lafontant JG, Hightower AW, Lammie PJ. Randomised placebo-controlled comparison of ivermectin and albendazole and in combination for
Wuchereria bancrofti microfilaraemia in Haitian children. Lancet 1997;350: 480-484
https://doi.org/10.1016/S0140-6736(97)02231-9.
196. Ismail MM, Jayakody RL, Weil GJ, Nirmalan N, Jayasinghe KS, Abeyewickrema W, Rezvi Sheriff MH, Rajaratnam HN, Amarasekera N, de Silva DC, Michalski ML, Dissanaike AS. Efficacy of single dose combinations of albendazole, ivermectin and diethylcarbamazine for the treatment of bancroftian filariasis. Trans R Soc Trop Med Hyg 1998;92: 94-97
https://doi.org/10.1016/S0035-9203(98)90972-5.
198. Pion SDS, Chesnais CB, Awaca-Uvon NP, Vlaminck J, Abdou A, Kunyu-Shako B, Kuyangisa Simuna G, Tambwe JP, Weil GJ, Boussinesq M. The impact of four years of semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Democratic Republic of Congo. PLoS Negl Trop Dis 2020;14: e0008322
https://doi.org/10.1371/journal.pntd.0008322.
199. Ottesen EA, Duke BO, Karam M, Behbehani K. Strategies and tools for the control/elimination of lymphatic filariasis. Bull World Health Organ 1997;75: 491-503.
200. Shenoy RK, Dalia S, John A, Suma TK, Kumaraswami V. Treatment of the microfilaraemia of asymptomatic brugian filariasis with single doses of ivermectin, diethylcarbamazine or albendazole, in various combinations. Ann Trop Med Parasitol 1999;93: 643-651
https://doi.org/10.1080/00034983.1999.11813467.
201. Fischer P, Djuardi Y, Ismid IS, Rückert P, Bradley M, Supali T. Long-lasting reduction of
Brugia timori microfilariae following a single dose of diethylcarbamazine combined with albendazole. Trans R Soc Trop Med Hyg 2003;97: 446-448
https://doi.org/10.1016/S0035-9203(03)90086-1.
202. Gyapong JO, Kumaraswami V, Biswas G, Ottesen EA. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opin Pharmacother 2005;6: 179-200
https://doi.org/10.1517/14656566.6.2.179.
204. Critchley J, Addiss D, Ejere H, Gamble C, Garner P, Helband H. Albendazole for the control and elimination of lymphatic filariasis: systematic review. Trop Med Int Health 2005;10: 818-825
https://doi.org/10.1111/j.1365-3156.2005.01458.x.
205. Macfarlane CL, Budhahoki SS, Johnson S, Richardson M, Garner P. Albendazole along or in combination with microfilaricidal drugs for lymphatic filariasis (Review). Cochrane Datab Syst Rev; 2019. 1: CD003753
https://doi.org/10.1002/14651858.CD00-3753.pib4.
206. Kar SK, Dwibedi B, Das BK, Agrawala BK, Ramachandran CP, Horton J. Lymphatic pathology in asymptomatic and symptomatic children with
Wuchereria bancrofti infection in children from Odisha, India and its reversal with DEC and albendazole treatment. PLoS Negl Trop Dis 2017;11: e0005631
https://doi.org/10.1371/journal.pntd.0005631.
207. Edi C, Bjerum CM, Ouattara AF, Chhonker YS, Penali LK, Méité A, Koudou BG, Weil GJ, King CL, Murry DJ. Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without
Wuchereria bancrofti infection in Côte d’Ivoire. PLoS Negl Trop Dis 2019;13: e0007325
https://doi.org/10.1371/journal.pntd.0007325.
208. Jambulingam P, Kuttiatt VS, Krishnamoorthy K, Subramanian S, Srividya A, Raju HKK, Rahi M, Somani RK, Suryaprakash MK, Dwivedi GP, Weil GJ. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India. PLoS Negl Trop Dis 2021;15: e0009069
https://doi.org/10.1371/journal.pntd.0009069.
209. Turner JD, Mad S, Debrah AY, Muehlfeld J, Pfarr K, McGarry HF, Adjei O, Taylor MJ, Hoerauf A. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of
Wuchereria bancrofti infection. Clin Infect Dis 2006;42: 1081-1089
https://doi.org/10.1086/501351.
210. Sarma RVSN, Vallishayee RS, Rao RSN, Prabhakar R, Tripathy SP. Use of mebendazole in combination with DEC in bancroftian filariasis. Indian J Med Res 1988;87: 579-583
https://eprints.nirt.res.in/242/.
211. Awadzi K, Edwards G, Duke BOL, Opoku NO, Attah SK, Addy ET, Ardrey AE, Quartey BT. The co-administration of ivermectin and albendazole-safety, pharmacokinetics and efficacy against
Onchocerca volvulus. Ann Trop Med Parasitol 2003;97: 165-178
https://doi.org/10.1179/000349803235001697.
213. Cline BL, Hernandez JL, Mather FJ, Bartholomew R, Maza SN, Rodulfo S, Welborn CA, Eberhard ML, Convit J. Albendazole in the treatment of onchocerciasis: double-blind clinical trial in Venezuela. Am J Trop Med Hyg 1992;47: 512-520
https://doi.org/10.4269/ajtmh.1992.47.512.
214. Awadzi K, Addy ET, Opoku NO, Plenge-Bönig A, Büttner DW. The chemotherapy of onchocerciasis. XX. Ivermectin in combination with albendazole. Trop Med Parasitol 1995;46: 213-220
https://europepmc.org/article/med/8826100.
215. Batsa Debrah L, Klarmann-Schulz U, Osei-Mensah J, Dubben B, Fischer K, Mubarik Y, Ayisi-Boateng NK, Ricchiuto A, Fimmers R, Konadu P, Nadal J, Gruetzmacher B, Weil G, Kazura JW, King CL, Debrah AY, Hoerauf A. Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for the treatment of onchocerciasis: a randomized, open-label, clinical trial. Clin Infect Dis 2020;71: 933-943
https://doi.org/10.1093/cid/ciz889.
217. Klarmann-Schulz U, Specht S, Debrah AY, Batsa L, Ayisi-Boateng NK, Osei-Mensah J, Mubarik Y, Konadu P, Ricchiuto A, Fimmers R, Arriens S, Dubben B, Ford L, Taylor M, Hoerauf A. Comparison of doxycycline, minocycline, doxycycline plus albendazole and albendazole alone in their efficacy against onchocerciasis in a randomized, open-label, pilot trial. PLoS Negl Trop Dis 2017;11: e0005156
https://doi.org/10.1371/journal.pntd.0005156.
218. Fischer PU, King CL, Jacobson JA, Weil GJ. Potential value of triple drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa. PLoS Negl Trop Dis 2017;11: e0005163
https://doi.org/10.1371/journal.pntd.0005163.
221. Taylor HR, Awadzi K, George T, Schulz-Key H, Murphy RP. Fluorescein angiographic studies of mebendazole treatment for onchocerciasis. Trop Med Parasitol 1985;36: 7-11
https://europepmc.org/article/med/4001769.
222. Rivas-Alcalá AR, Greene BM, Taylor HR, Domíguez-Vázquez A, Ruvalcaba-Macías AM, Lugo-Pfeiffer C, Mackenzie CD, Beltrán F. Chemotherapy of onchocerciasis: a controlled comparison of mebendazole, levamisole, and diethylcarbamazine. Lancet 1981;318: 485-490
https://doi.org/10.1016/S0140-6736(81)90880-1.
223. Awadzi K, Schulz-Key H, Howells RE, Haddock DRW, Gilles HM. The chemotherapy of onchocerciasis. VIII. Levamisole and its combination with the benzimidazoles. Ann Trop Med Parasitol 1982;76: 459-473
https://doi.org/10.1080/00034983.1982.11687567.
225. Awadzi K, Edwards G, Opoku NO, Ardrey AE, Favager S, Addy ET, Attah SK, Yamuah LK, Quartey BT. The safety, tolerability and pharmacokinetics of levamisole alone, levamisole plus ivermectin, and levamisole plus albendazole, and their efficacy against
Onchocerca volvulus. Ann Trop Med Parasitol 2004;98: 595-614
https://doi.org/10.1079/000349804225021370.
226. Klion AD, Massougbodji A, Horton J, Ekoué S, Lanmasso T, Ahouissou NL, Nutman TB. Albendazole in human loiasis: results of a double-blind, placebo-controlled trial. J Infect Dis 1993;168: 202-206
https://doi.org/10.1093/infdis/168.1.202.
227. Klion AD, Horton J, Nutman TB. Albendazole therapy for loiasis refractory to diethylcarbamazine treatment. Clin Infect Dis 1999;29: 680-682
https://doi.org/10.1086/598654.
228. Arrey-Agbor DB, Nana-Djeunga HC, Mogoung-Wafo AE, Mafo M, Danwe C, Kamgno J. Case report: probable case of spontaneous encephalopathy due to loiasis and dramatic reduction of
Loa loa microfilaraemia with prolonged repeated courses of albendazole. Am J Trop Med Hyg 2018;99: 112-115
https://doi.org/10.4269/ajtmh.17-0664.
229. Gobbi F, Buonfrate D, Tamarozzi F, Degani M, Angheben A, Bisoffi Z. Efficacy of high-dose albendazole with ivermectin for treating imported loiasis, Italy. Emerg Infect Dis 2019;25: 1574-1576
https://doi.org/10.3201/eid2508.190011.
230. Tabi TE, Befidi-Mengue R, Nutman TB, Horton J, Folefack A, Pensia E, Fualem R, Fogako J, Gwanmesia P, Quakyi I, Leke R. Human loiasis in a Cameroonian village: a double-blind, placebo-controlled, crossover clinical trial of a three-day albendazole regimen. Am J Trop Med Hyg 2004;71: 211-215
https://doi.org/10.4269/ajtmh.2004.71.211.
231. Tsague-Dongmo L, Kamgno J, Pion SDS, Moyou-Somo R, Boussinesq M. Effects of a 3-day regimen of albendazole (800 mg daily) on
Loa loa microfilaraemia. Ann Trop Med Parasitol 2002;96: 707-715
https://doi.org/10.1179/000349802125001933.
232. Richard-Lenoble D, Komblia M, Burnier I, Maganga ML. Filariasis in Gabon: treatment with mebendazole of filariasis due to Mansonella perstans and Loa loa. Bull Soc Pathol Rxot Filial 1985;78: 485-491 (in French). https://europepmc.org/article/med/3865739.
234. Van Hoegaerden M, Ivanoff B, Flocard F, Salle A, Chabaud B. The use of mebendazole in the treatment of filariasis due to
Loa loa and
Mansonella perstans. Ann Trop Med Parasitol 1987;81: 275-282
https://doi.org/10.1080/00034983.1987.11812120.
238. Puente S, Lago M, Subirats M, Sanz-Esteban I, Arsuaga M, Vicente B, Alonso-Sardon M, Behlhassen-Garcia M, Muro A. Imported
Mansonella perstans infection in Spain. Infect Dis Poverty 2020;9: 105
https://doi.org/10.1186/s40249-020-00729-9.
241. Duong TH, Kombila M, Ferrer A, Nguiri C, Richard-Lenoble D. Decrease in
Mansonella perstans microfilaraemia after albendazole treatment. Trans R Soc Trop Med Hyg 1998;92: 459
https://doi.org/10.1016/S0035-9203(98)91093-8.
242. Asio SM, Simonsen PE, Onapa AW.
Mansonella perstans: safety and efficacy of ivermectin alone, albendazole alone and the two drugs in combination. Ann Trop Med Parasitol 2009;103: 31-37
https://doi.org/10.1179/136485909X384929.
244. Debrah LB, Phillips RO, Pfarr K, Klarmann-Schulz U, Opoku VS, Nausch N, Owusu W, Mubarik Y, Sander AL, Lämmer C, Ritter M, Layland LE, Jacobsen M, Debrah AY, Hoerauf A. The efficacy of doxycycline treatment on
Mansonella perstans infection: an open-label, randomized trial in Ghana. Am H Trop Med Hyg 2019;101: 84-92
https://doi.org/10.4269/ajtmh.18-0491.
247. Bregani ER, Rovellini A, Mbaidoum N, Magnini MG. Comparison of different anthelmintic drug regimens against
Mansonella perstans filariasis. Trans R Soc Trop Med Hyg 2006;100: 458-463
https://doi.org/10.1016/j.trstmh.2005.07.009.
248. Simón F, Siles-Lucas M, Morchón R, González-Miguel J, Mellado I, Carretán E, Montoya-Alonso JA. Human and animal dirofilariasis: the emergence of a zoonotic mosaic. Clin Microbiol Rev 2012;25: 507-544
https://doi.org/10.1128/CMR.00012-12.
249. GheorghiŢă MI, ForŢofoiu MC, Dumitrescu CI, Dumitrescu D, Camen A, Mărgăritescu C. Intramuscular human
Dirofilaria repens infection of the temporal region-case report and review of literature. Rom J Morphol Embryol 2017;58: 585-592.
254. Ronald NC, Crag TM, Bell RR. A controlled evaluation of albendazole against natural infections with
Fasciola hepatica and
Fascioloides magna in cattle. Am J Vet Res 1979;40: 1299-1300.
255. Fetterer R, Rew RS, Knight R. Comparative efficacy of albendazole against
Fasciola hepatica in sheep and calves: relationship to serum drug metabolite levels. Vet Parasitol 1982;11: 309-316
https://doi.org/10.1016/0304-4017(82)90099-1.
257. Apt W, Aguilera X, Vega F, Miranda C, Zulantay I, Perez C, Gabor M, Apt P. Treatment of human chronic fascioliasis with triclabendazole: drug efficacy and serologic response. Am J Trop Med Hyg 1995;52: 532-535
https://doi.org/10.4269/ajtmh.1995.52.532.
258. Zali AH, Ghaziani T, Shahraz S, Hekmatdoost A, Radmehr A. Liver, spleen, pancreas and kidney involvement by human fascioliasis: imaging findings. BMC Gastroenterol 2004;4: 15
https://doi.org/10.1186/1471-230X-4-15.
260. Robinson MW, Lawson J, Trudgett A, Hoey EM, Fairweather I. The comparative metabolism of triclabendazole sulphoxide by triclabendazole–susceptible and triclabendazole-resistant
Fasciola hepatica. Parasitol Res 2004;92: 205-210
https://doi.org/10.1007/s00436-003-1003-6.
261. Arauco R, Zetola NM, Calderon F, Seas C. Human fascioliasis: a case of hyperinfection and an update for clinicians. Foodborne Pathog Dis 2007;4: 305-312
https://doi.org/10.1089/fpg.2007.0001.
267. Meloni BP, Thompson RCA, Reynoldson JA, Seville P. Albendazole: a more effective antigiardial agent in vitro than metronidazole or tinidazole. Trans R Soc Trop Med Hyg 1990;84: 375-379
https://doi.org/10.1016/0035-9203(90)90324-8.
268. Reynoldson JA, Thompson RCA, Meloni BP. In vivo efficacy of albendazole against
Giardia duodenalis in mice. Parasitol Res 1991;77: 325-328
https://doi.org/10.1007/BF00930909.
270. Oxberry ME, Thompson RCA, Reynoldson JA. Evaluation of the effects of albendazole and metronidazole on the ultrastructure of
Giardia duodenalis,
Trichomonas vaginalis and
Spironucleus muris using transmission electron microscopy. Int J Parasitol 1994;24: 695-703
https://doi.org/10.1016/0020-7519(94)90123-6.
274. Cacopardo B, Patamia I, Bonaccorso V, Paola O, Bonforte S, Brancati G. Synergic effect of albendazole plus metronidazole association in the treatment of metronidazole-resistant giardiasis. Clin Ther 1995;146: 761-767 (in Italian). https://europepmc.org/article/med/8681495.
275. Mørch K, Hanevik K, Robertson LJ, Strand EA, Langeland N. Treatment-ladder and genetic characterization of parasites in refractory giardiasis after an outbreak in Norway. J Infect 2008;56: 268-273
https://doi.org/10.1016/j.jinf.2008.01.013.
277. Argüello-García R, Leitsch D, Skinner-Adams T, Ortega-Pierres MG. Drug resistance in
Giardia: mechanisms and alternative treatments for giardiasis. Adv Parasitol 2020;107: 201-282
https://doi.org/10.1016/bs.apar.2019.11.003.
278. Hutchison JG, Johnston NM, Plevey MV, Thankhiew I. Aidney C. Clinical trial of mebendazole, a broad-spectrum anthelminthic. Br Med J 1975;2: 309-310
https://doi.org/10.1136/bmj.2.5966.309.
282. Katiyar SK, Gordon VR, McLaughlin GL, Edlind TD. Antiprotozoal activities of benzimidazoles and correlations with β-tubulin sequence. Antimicrob Agents Chemother 1994;38: 2086-2090
https://doi.org/10.1128/AAC.38.9.2086.
283. Goodhew EB, Secor EV. Drug library screening against metronidazole-sensitive and metronidazole-resistant
Trichomonas vaginalis isolates. Sex Transm Infect 2013;89: 479-484
https://doi.org/10.1136/sextrans-2013-051032.
285. Cañete R, Escobedo AA, Almirall P, González ME, Brito K, Cimerman S. Mebendazole in parasitic infections other than those caused by soil-transmitted helminths. Trans R Soc Trop Med Hyg 2009;103: 437-442
https:/doi/org/10.1016/j.trstmh.2008.11.029.
286. Pattman RS, Sprott MS, Kearns AM, Earnshaw M. Failure of mebendazole to cure trichomonal vaginitis resistant to metronidazole: case reports. Genitourin Med 1989;65: 274-275
http://dx.doi.org/10.1136/sti.65.4.274.
287. McDonald LM, Armson A, Thompson RCA, Reynoldson JA. Characterisation of benzimidazole binding with recombinant tubulin from
Giardia duodenalis,
Encephalitozoon intestinalis, and
Cryptosporidium parvum. Mol Biochem parasitol 2004;138: 89-96
https://doi.org/10.1016/j.molbiopara.2004.08.001.
288. Fayer R, Fetterer R. Activity of benzimidazoles against cryptosporidiosis in neonatal BALB/c mice. J Parasitol 1995;81: 794-795
https://doi.org/10.2307/3283980.
289. Weiss LM. Chapter 109. Microsporidiosis. In Ryan ET, Hill DR, Solomon T, Aronson NE, Endy TP eds, Hunter’s Tropical Medicine and Emerging Infectious Diseases. 10th ed. Edinburgh, Scotland. Elsevier. 2020, pp 825-831
https://doi.org/10.1016/B978-0-323-55512-8.00109-5.
291. Nacey CJ, Clarke AM, Fraser P, Metcalfe T, Bonsor G, Curry A. Chronic microsporidian infection of the nasal mucosae, sinuses and conjunctivae in HIV disease. Genitourin Med 1992;68: 179-181
http://doi.org/10.1136/sti.68.3.179.
292. Deplazes P, Mathis A, Baumgartner R, Tanner I, Weber R. Immunologic and molecular characteristics of
Encephalitozoon-like microsporidia isolated from humans and rabbits indicate that
Encephalitozoon cuniculi is a zoonotic parasite. Clin Infect Dis 1996;22: 557-559
https://doi.org/10.1093/clinids/22.3.557.
293. Hocevar SN, Paddock CD, Spak CW, Rosenblatt R, Diaz-Luna H, Castillo I, Luna S, Friedman GC, Antony S, Stoddard RA, Tiller RV, Peterson T, Blau DM, Sriam RR, da Silva A, de Almeida M, Benedict T, Goldsmith CS, Zaki SR, Visvesvara GS, Kuehnert MJ. Microsporidiosis acquired through solid organ transplantation: a public health investigation. Ann Intern Med 2014;160: 213-220
https://doi.org/10.7326/M13-2226.
294. Dore GJ, Marriott DJ, Hing MC, Harkness JL, Field AS. Disseminated microsporidiosis due to
Septata intestinalis in nine patients infected with the human immunodeficiency virus: response to therapy with albendazole. Clin Infect Dis 1995;21: 70-76
https://doi.org/10.1093/clinids/21.1.70.
296. Molina JM, Chastang C, Goguel J, Michiels JF, Sarfati C, Desportes-Livage I, Horton J, Derouin F, Modaï J. Albendazole for treatment and prophylaxis of microsporidiosis due to
Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial. J Infect Dis 1998;177: 1373-1377
https://doi.org/10.1086/515268.
297. Leder K, Ryan N, Spelman D, Crowe SM. Microsporidial disease in HIV-infected patients: a report of 42 patients and review of the literature. Scand J Infect Dis 1998;30: 331-338
https://doi.org/10.1080/00365549850160594.
298. Tremoulet AH, Avila-Aguero ML, París MM, Canas-Coto A, Ulloa-Gutierrez R, Faingezicht I. Albendazole therapy for
Microsporidium diarrhea in immunocompetent Coasta Rican children. Ped Infect Dis J 2004;23: 915-918
https://doi.org/10.1097/01.inf.0000141724.06556.f9.
299. Molina JM, Sarfati C, Beauvais B, Lémann M, Lesourd A, Ferchal F, Casin I, Lagrange P, Modigliani R, Derouin F, Modal J. Intestinal microsporidiosis in human immunodeficiency virus-infected patients with chronic unexplained diarrhea: prevalence and clinical and biological features. J Infect Dis 1993;167: 217-221
https://doi.org/10.1093/infdis/167.1.217.
300. Dieterich DT, Lew EA, Kotler DP, Poles MA, Orenstein JM. Treatment with albendazole for intestinal disease due to
Enterocytozoon bieneusi in patients with AIDS. J Infect Dis 1994;169: 178-183
https://doi.org/10.1093/infdis/169.1.178.
301. Wichro E, Hoelzi D, Krause R, Bertha G, Reinthaler F, Wenisch C. Microsporidiosis in travel-associated chronic diarrhea in immune-competent patients. Am J Trop Med Hyg 2005;73: 285-287
https://doi.org/10.4269/ajtmh.2005.73.285.
302. Galván AL, Sánchez AMM, Pérez Valentín MA, Henriques-Gil N, Izquierdo F, Fenoy S, del Aguila C. First cases of microsporidiosis in transplant recipients in Spain and review of the literature. J Clin Microbiol 2011;49: 1301-1306
https://doi.org/10.1128/JCM.01833-10.
303. Molina JM, Goguel J, Sarfati C, Michiels JF, Desportes-Livage I, Balkan S, Chastang C, Cotte L, Maslo C, Struxiano A, Derouin F, Decazes JM. Trial of oral fumagillin for the treatment of intestinal microsporidiosis in patients with HIV infection. AIDS 2000;14: 1341-1348.
304. Lanternier F, Boutboul D, Menotti J, Chandesris MO, Sarfati C, Mamzer Bruneel MF, Calmus Y, Mechaï F, Viard JP, Lecuit M, Bougnoux ME, Lortholary O. Microsporidiosis in solid organ transplant recipient: two
Enterocytozoon bieneusi cases and review. Transpl Infect Dis 2009;11: 83-88
https://doi.org/10.1111/j.1399-3062.2008.00347.x.
305. George B, Coates T, McDonald S, Russ G, Cherian S, Nolan J, Brealey J. Disseminated microsporidiosis with
Encephalitozoon species in a renal transplant recipient. Nephrology 2012;17(suppl):5-8
https://doi.org/10.1111/k.1440-1797.2012.01580.x.
306. Boileau M, Ferreira J, Ahman I, Lavallee C, Qvarnstrom Y, Dufresne SF. Successful treatment of disseminated
Anncalia algerae microsporidial infection with combination fumagillin and albendazole. Open Forum Infect Dis 2016;3: 1-4
https://doi.org/10.1093/ofid/ofw158.
307. Katiyar SK, Edlind TD. In vitro susceptibilities of the AIDS-associated microsporidian
Encephalitozoon intestinalis to albendazole, its sulfoxide metabolite, and 12 additional benzimidazole derivatives. Antimicrob Agents Chemother 1997;41: 2729-2732
https://doi.org/10.1128/AAC.41.12.2729.
312. Ben Fredj N, Chaabane A, Chadly Z, Ben Fadhel N, Boughattas NA, Aouam K. Albendazole-induced associated acute hepatitis and bicytopenia. Scand J Infect Dis 2014;46: 149-151
https://doi.org/10.3109/00365548.2013.835068.
313. Pourgholami MH, Szwajcer M, Chin M, Liauw W, Seef J, Galettis P, Morris DL, Links M. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer. Cancer Chemother Pharmacol 2010;65: 597-605
https://doi.org/10.1007/s00280-009-1157-8.
316. Marin Zuluaga JI, marin Castro AE, Perez Cadavid JC, Restrepo Guttierez JC. Albendazole-induced granulomatous hepatitis: a case report. J Med Case Rep 2013;7: 201
https://doi.org/10.1186/1752-1947-7-201.
318. Narciso-Schiavon JL, Delziovo HA, Santos LEB, Shiozawa MBC, Schiavon LL. Recurrent albendazole-induced acute hepatitis. Rev Colomb Gastroenterol 2018;33: 463-467 (in Spanish).
https://doi.org/10.22516/25007440.206.
319. Amoruso C, Fuoti M, Miceli V, Zito E, Celano MR, De Giorgi A, Nebbia G. Acute hepatitis as a side effect of albendazole: a pediatric case. Pediatr Med Chir; 2009. 31: 176-178 (in Italian).
https://europepmc.org/article/med/19839402.
322. Grama A, Aldea CO, Burac L, Delean D, Bulata B, Sirbe C, Duca E, Boghitoiu D, Coroleuca A, Pop TL. Etiology and outcome of acute liver failure in children-The experience of a single tertiary care hospital from Romania. Children 2020;7: 282
https://doi.org/10.3390/children7120282.
323. Batzlaff CM, Pupaibool J, Sohail MR. Acute renal failure associated with albendazole therapy in a patient with trichinosis. BMJ Case Rep; 2014. 2014: bcr2013200668.
https://doi.org/10.1136/bcr-2013-200668.
324. Tolomeo M, Colomba C, Meli M, Cascio A. Hepatotoxicity caused by mebendazole in a patient with Gilbert’s syndrome. J Clin Pharm Ther 2019;44: 985-987
https://doi.org/10.1111/jcpt.13033.
325. Seitz R, Schwerk W, Arnold R. Hepatocellular drug reaction caused by mebendazole therapy in cystic echinococcosis. Z Gastroenterol 1983;21: 324-329 (in German).
https://europepmc.org/article/med/6613213.
328. Chen KT, Twu SJ, Chang HJ, Lin RS. Outbreak of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. Am J Public Health 2003;93: 489-492
https://doi.org/10.2105/ajph.93.3.489.
329. Kwa MSG, Veenstra JG, Roos MH. Benzimidazole resistance in
Haemonchus contortus is correlated with a conserved mutation at amino acid 200 in β-tubulin isotype 1. Mol Biochem Parasitol 1994;63: 299-303
https://doi.org/10.1016/0166-6851(94)90066-3.
330. De Clercq D, Sacko M, Behnke J, Gilbert F, Dorny P, Vercruysse J. Failure of mebendazole in treatment of human hookworm infections in the southern region of Mali. Am J Trop Med Hyg 1997;57: 25-30
https://doi.org/10.4269/ajtmh.1997.57.25.
331. Furtado LVF, Bello ACP, dos Santos HA, Carvalho MRS, Rabelo ÉML. First identification of the F200Y SNP in the β-tubulin gene linked to benzimidazole resistance in
Ancylostoma caninum. Vet Parasitol 2014;206: 313-316
https://doi.org/10.1016/j.vetpar.2014.10.021.
332. Jaeger LH, Carvalho-Costa FA. Status of benzimidazole resistance in intestinal nematode populations of livestock in Brazil: a systematic review. BMC Vet Res 2017;13: 358
https://doi.org/10.1186/s12917-017-1282-2.
333. Furtado LFV, de Aguiar PHN, Zuccherato LW, Teixeira TTG, Alves WP, da Silva VJ, Gasser RB, Rabelo ÉML. Albendazole resistance induced in
Ancylostoma ceylanicum is not due to single-nucleotide polymorphisms (SNPs) at codons 167, 198, or 200 of the beta-tubulin gene, indicating another resistance mechanism. Parasitol Res 2019;118: 837-849
https://doi.org/10.1007/s00436-019-06218-9.
335. Albonico M, Wright V, Bickle Q. Molecular analysis of the β-tubulin gene of human hookworms as a basis for possible benzimidazole resistance on Pemba Island. Mol Biochem Parasitol 2004;134: 281-284
https://doi.org/10.1016/j.molbiopara.2003.12.008.
337. Albonico M, Bickle Q, Ramsan M, Montresor A, Savioli L, Taylor M. Efficacy of mebendazole and levamisole alone or in combination against intestinal nematode infections after repeated targeted mebendazole treatment in Zanzibar. Bull World Health Organ 2003;81: 343-352 https://www.scielosp.org/article/bwho/2003.v81n5/343-352/en/.
338. Flohr C, Tuyen L, Lewis S, Minh TT, Campbell J, Britton J, Williams H, Hien TT, Farrar J, Quinnell RJ. Low efficacy of mebendazole against hookworm in Vietnam: two randomized controlled trials. Am J Trop Med Hyg 2007;76: 732-736
https://doi.org/10.4269/ajtmh.2007.76.732.
339. Humphries D, Mosites E, Otchere J, Twum WA, Woo L, Jones-Sanpei H, Harrison LM, Bungiro RD, Benham-Pyle B, Bimi L, Edoh D, Bosompem K, Wilson M, Cappello M. Epidemiology of hookworm infection in Kintampo North Municipality, Ghana: patterns of malaria coinfection, anemia, and albendazole treatment failure. Am J Trop Med Hyg 2011;84: 792-800
https://doi.org/10.4269/ajtmh.2011.11-0003.
340. Diawara A, Drake LJ, Suswillo RR, Kihara J, Bundy DAP, Scott ME, Halpenny C, Stothard JR, Prichard RK. Assays to detect β-tubulin codon 200 polymorphism in
Trichuris trichiura and
Ascaris lumbricoides. PLoS Negl Trop Dis 2009;3: e397
https://doi.org/10.1371/journal.pntd.0000397.
341. Diawara A, Halpenny C, Churcher TS, Mwandawiro C, Kihara J, Kaplan RM, Streit TG, Idaghdour Y, Scott ME, Basáñez MG, Prichard RK. Association between response to albendazole treatment and β-tubulin frequencies in soil-transmitted helminths. PLoS Negl Trop Dis 2013;7: e2247
https://doi.org/10.1371/journal.pntd.0002247.
342. Vercruysse J, Behnke JM, Albonico M, Ame SM, Angebault C, Bethony JM, Engels D, Guillard B, Nguyen TV, Kang G, Kattula D, Kotze AC, McCarthy JS, Mekonnen Z, Montresor A, Periago MV, Sumo L, Tchuenté LA, Dang TC, Zeynudin A, Levecke B. Assessment of the anthelmintic efficacy of albendazole in school children in seven countries where soil-transmitted helminths are endemic. PLoS Negl Trop Dis 2011;5: e948
https://doi.org/10.1371/journal.pntd.0000948.
343. Schwab AE, Boakye DA, Kyelem D, Prichard RK. Detection of benzimidazole resistance-associated mutations in the filarial nematode
Wuchereria bancrofti and evidence for selection by albendazole and ivermectin combination treatment. Am J Trop Med Hyg 2005;73: 234-238
https://doi.org/10.4269/ajtmh.2005.73.234.
344. Upcroft J, Mitchell R, Chen N, Upcroft P. Albendazole resistance in
Giardia is correlated with cytoskeletal changes but not with a mutation at amino acid 200 in β-tubulin. Microb Drug Resist 1996;2: 303-308
https://doi.org/10.1089/mdr.1996.2.303.
345. Lacey E, Watson TR. Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: correlation with in vitro tubulin polymerization assay. Biochem Pharmacol 1985;34: 3603-3605
https://doi.org/10.1016/0006-2952(85)90742-7.
346. Rolin S, Amri HS, Batt AM, Levy M, Bagrel D, Siest G. Study of the in vitro bioactivation of albendazole in human liver microsomes and hepatic cell lines. Cell Biol Toxicol 1989;5: 1-14
https://doi.org/10.1007/BF00141060.
347. Pourgholami MH, Cai ZY, Lu Y, Wang L, Morris DL. Albendazole; a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. Clin Cancer Res 2006;12: 1928-1935
https://doi.org/10.1158/1078-0432.CCR-05-1181.
348. Ehteda A, Galettis P, Pillai K, Morris DL. Combination of albendazole and 2-methoxyestradiol significantly improves the survival of HCT-116 tumor-bearing nude mice. BMC Cancers 2013;13: 86
https://doi.org/10.1186/1471-2407-13-86.
349. Javdan S, Nayeri H, Vaseghi G. Cytotoxic effect of albendazole on the breast cancer and melanoma. Zahedan J Res Med Sci 2018;20: e9100
https://doi.org/10.5812/zjrms.9100.
350. Priotti J, Baglioni V, García A, Rico MJ, Leonardi D, Lamas MC, Márquez MM. Repositioning of anti-parasitic drugs in cyclodextrin inclusion complexes for treatment of triple-negative breast cancer. AAPS PharmEciTech 2018;19: 3734-3741
https://doi.org/10.1208/s12249-018-1169-y.
353. Zhang X, Zhao J, Gao X, Pei D, Gao C. Anthelmintic drug albendazole arrests human gastric cancer cells at the mitotic phase and induces apoptosis. Exp Ther Med 2017;13: 595-603
https://doi.org/10.3892/etm.2016.3992.
354. Yang MH, Ha IJ, Um JY, Ahn KS. Albendazole exhibits anti-neoplastic actions against gastric cancer cells by affecting STAT3 and SATAT5 activation by pleiotropic mechanism(s). Biomedicines 2021;9: 362
https://doi.org/10.3390/biomedicines9040362.
355. Ghasemi F, Black M, Vizeacoumar F, Pinto N, Ruicci KM, Le CCSH, Lowerison MR, Leong HS, Yoo J, Fung K, MacNeil D, Palma DA, Winquist E, Mymryk JS, Boutros PC, Datti A, Barrett JW, Nichols AC. Repurposing albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer. Oncotarget 2017;8: 71512-71519
https://doi.org/10.18632/oncotarget.17292.
356. Zhang QL, Lian DD, Zhu MJ, Li XM, Lee JK, Yoon TJ, Lee JH, Jiang RH, Kim CD. Antitumor effect of albendazole on cutaneous squamous cell carcinoma (SCC) cells. BioMed Res Int 2019;2019: 3689517
https://doi.org/10.1155/2019/3689517.
357. Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Sci Rep 2018;8: 11926
https://doi.org/10.1038/s41598-018-30158-6.
358. Movahedi F, Li L, Gu W, Xu ZP. Nanoformulations of albendazole as effective anticancer and antiparasite agents. Nanomedicine 2017;12: 2555-2574
https://doi.org/10.2217/nnm-2017-0102.
359. Racoviceanu R, Trandafirescu C, Voicu M, Ghiulai R, Borcan F, Dehelean C, Watz C, Aigner Z, Ambrus R, Coricovac DE, Cîrcioban D, Mioc A, Szuhanek CA, Şoica C. Solid polymeric nanoparticles of albendazole: synthesis, physico-chemical characterization and biological activity. Molecules 2020;25: 5130
https://doi.org/10.3390/molecules25215130.
360. Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res 2002;8: 2963-2969.
361. Sasaki J, Ramesh R, Chada S, Gomyo Y, Roth JA, Mukhopadhyay T. The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells. Mol Cancer Therapeut 2002;1: 1201-1209 https://mct.aacrjournals.org/content/1/13/1211.full-text.pdf.
362. Martarelli D, Pompei P, Baldi C, Mazzoni G. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol 2008;61: 809-817
https://doi.org/10.1007/s00280-007-0538-0.
364. Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro-Oncology 2011;13: 974-982
https://doi.org/10.1093/neuonc/nor077.
365. Nygren P, Fraknäs M, Ågerup B, Larsson R. Repositioning of the anthelmintic drug mebendazole for the treatment for colon cancer. J cancer Res Clin Oncol 2013;139: 2133-2140
https://doi.org/10.1007/s00432-013-1539-5.
366. De Witt M, Gamble A, Hanson D, Markowitz D, Powell C, Dimassi SA, Atlas M, Boockvar J, Ruggieri R, Symons M. Repurposing mebendazole as a replacement for vincristine for the treatment of brain tumors. Mol Med 2017;23: 50-56
https://doi.org/10.2119/molmed.2017.00011.
367. Lai SR, Castello SA, Robinson AC, Koehler JW. In vitro anti-tubulin effects of mebendazole and fenbendazole in canine glioma cells. Vet Comp Oncol 2017;15: 1445-1454
https://doi.org/10.1111/vco.12288.
368. Elayapillai S, Ramraj S, Benbrook DM, Bieniasz M, Wang L, Pathuri G, Isingizwe ZR, Kennedy AL, Zhao YD, Lightfoot S, Hunsucker LA, Gunderson CC. Potential and mechanism of mebendazole for treatment and maintenance of ovarian cancer. Gynecol Oncol 2021;160: 302-311
https://doi.org/10.1016/j.ygyno.2020.10.010.
369. Rushworth LK, Hewit K, Munnings-Tomes S, Somani S, James D, Shanks E, Dufes C, Straube A, Patel R, Leung HY. Repurposing screen identifies mebendazole as a clinical candidate to synergise with docetaxel for prostate cancer treatment. Br J Cancer 2020;122: 517-527
https://doi.org/10.1038/s41416-019-0681-5.
370. Dobrosotskaya IY, Hammer GD, Schteingart DE, Maturen KE, Worden FP. Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. Endocr Pract 2011;17: e59-e62
https://doi.org/10.4158/EP10390.CR.
371. Nygren P, Larsson R. Drug repositioning from bench to bedside: tumor remission by the antihelmintic drug mebendazole in refractory metastatic colon cancer. Acta Oncol 2014;53: 427-428
https://doi.org/10.3109/0284186X.2013.844359.